Eli Lilly and Company (NYSE:LLY) Stock Position Increased by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich boosted its position in Eli Lilly and Company (NYSE:LLY) by 12.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 555,002 shares of the company’s stock after purchasing an additional 60,538 shares during the quarter. Eli Lilly and Company comprises 1.7% of Bank Julius Baer & Co. Ltd Zurich’s holdings, making the stock its 13th biggest position. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.06% of Eli Lilly and Company worth $323,522,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $27,000. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $35,000. Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $36,000. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $40,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $7.33 during trading hours on Thursday, hitting $724.87. 2,597,583 shares of the stock were exchanged, compared to its average volume of 3,034,002. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company’s 50 day moving average is $763.40 and its 200 day moving average is $664.52. The firm has a market capitalization of $688.74 billion, a P/E ratio of 124.61, a P/E/G ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a one year low of $370.68 and a one year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.09 EPS. On average, research analysts expect that Eli Lilly and Company will post 12.52 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.